All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-CD79B (MA79b) h(CD28-41BB-CD3z) CAR saRNA leverages the saRNA platform to express the MA79b clone. In vivo, this clone is highly valued for its proven clinical efficacy in targeting the CD79B component of the B-cell receptor. The biological magnification of saRNA ensures that a minimal systemic dose leads to robust CAR expression, enabling T cells to achieve the sensitivity required for in situ B-cell depletion in patients with aggressive or relapsed B-cell lymphomas.
There are currently no customer reviews or questions for VivoCAR™ Anti-CD79B (MA79b) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU76). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION